Introduction
============

Atherosclerosis (AS) is one of the leading causes of mortality in the world. It is a multistep cardiovascular disease promoted by several risk factors, including the accumulation of macrophages, production of pro-inflammatory cytokines and dysfunction of endothelial and vascular smooth muscle cells (VSMCs) ([@b1-mmr-19-06-4663]). Vascular remodeling is closely linked to the progression of AS, and the proliferation and migration of VSMCs is a major cellular event in hypertension- and diabetes-induced vascular remodeling ([@b2-mmr-19-06-4663]). However, the detailed mechanism underlying VSMC proliferation and migration in AS remains to be fully elucidated.

Long non-coding RNAs (lncRNAs) are RNA molecules present in eukaryotic cells, which are \>200 nucleotides long and are not translated into protein. lncRNAs are involved in several physiological and pathological processes, including carcinogenesis ([@b3-mmr-19-06-4663]) and cardiovascular diseases ([@b4-mmr-19-06-4663]). Recent evidence shows that lncRNAs are key in the development of AS by regulating gene expression at the transcriptional and post-transcriptional levels, which in turn influences multiple signaling pathways with respect to the proliferation and migration of VSMCs ([@b5-mmr-19-06-4663]--[@b7-mmr-19-06-4663]). This indicates that targeting lncRNAs in treating AS may be promising; however, the function of lncRNAs and the underlying mechanism by which they influence the proliferation and migration of VSMCs remain to be fully elucidated.

Receptor tyrosine kinase-like orphan receptor 2 (ROR2) is a member of the tyrosine kinase receptor family, which acts as a receptor of Wnt5a ([@b8-mmr-19-06-4663]). Wnt5a/ROR2 signaling primarily activates β-catenin-independent non-canonical Wnt pathways, which involve various signal mediators, including c-Jun N-terminal kinase, filamin A, Rous sarcoma oncogene (c-Src) and resistance to audiogenic seizures (Ras) homolog gene family member A (RhoA), thereby regulating cell proliferation and motility ([@b9-mmr-19-06-4663],[@b10-mmr-19-06-4663]). The sustained overactivation of RhoA is widely implicated in the pathogenesis of several cardiovascular disorders, including hypertension ([@b11-mmr-19-06-4663]). Previous studies have examined the regulation of RhoA by non-canonical Wnt signals and the transduction of non-canonical Wnt signaling by small Rho GTPases ([@b12-mmr-19-06-4663]), and increasing evidence supports to the role of lncRNAs in AS ([@b13-mmr-19-06-4663]). lncRNA ENST00000430945 (lncRNA 430945) is a large, intergenic non-coding RNA located on human chromosome 9q22.31. Microarray analysis and lncRNA-mRNA co-expression profiling has showed that lnc43094 is closely linked to the ROR2 signaling pathway. However, the specifics of lncRNA 430945-based ROR2 modulation in AS remain to be elucidated.

The present study investigated the role of lncRNAs and the putative molecular mechanisms by which they regulate VSMC proliferation and migration in AS. The expression of lncRNA 430945 was detected in human AS tissues and VSMCs, in addition to examining the proliferation and migration of angiotensin II (AngII)-induced VSMCs. The final aim was to elucidate the molecular mechanisms by which lncRNA 430945 regulates the expression of ROR2 and the proliferation and migration of VSMCs.

Materials and methods
=====================

### Reagents

Dulbecco\'s modified Eagle\'s medium (DMEM, Hyclone; GE Healthcare Life Sciences, Logan, UT, USA), fetal bovine serum (FBS, Gibco; Thermo Fisher Scientific, Waltham, MA, USA) and penicillin and streptomycin were purchased from Gibco (Thermo Fisher Scientific, Waltham, MA, USA). Anti-β-actin (cat. no. 60008-1-Ig), anti-RhoA (cat. no. 10749-1-AP), anti-proliferating cell nuclear antigen (PCNA; cat. no. 10205-2-AP), anti-matrix metallopeptidase 9 (MMP9; cat. no. 10375-2-AP) and anti-ROR2 (cat. no. 10616-1-AP) antibodies were purchased from ProteinTech Group, Inc., (Chicago, IL, USA). The lncRNA430945 expression vector, pcDNA-lncRNA430945, was synthetized and constructed by Guangzhou Ribobio Co., Ltd., (Guangzhou, China). Small interfering (si)RNA-lncRNA 430945 (si-lncRNA430945) and siRNA-ROR2 (si-ROR2) were obtained from Merck KGaA (Darmstadt, Germany). Cells were transfected with pcDNA-lncRNA 430945 or siRNAs using Lipofectamine^®^ 2000 (Invitrogen; Carlsbad, CA, USA) following the manufacturer\'s protocol.

### Human tissue harvest

The AS tissue specimens were obtained in the operating room from three male patients undergoing elective open aortic aneurysm repair. The mean age of the patients was 52 years (range, 47--63 years). Normal aortic wall tissue specimens were obtained from age-matched organ donors to serve as controls (n=3). All tissue specimens were collected at the Department of Cardiology, Tangshan Workers Hospital (Tangshan, China) between May 2017 and January 2018. All patients and healthy volunteers were well informed. One section of each aortic wall specimen was fixed overnight in 10% neutral-buffered formalin and processed for routine embedding in paraffin. An adjacent tissue region was snap-frozen in liquid nitrogen, stored at −80°C, and subsequently used for protein and nucleic acid extraction. The procedure of the experiment was approved by the Institutional Review Board of Hebei Medical University (Shijiazhuang, China) and written informed consent was obtained from all patients.

### Microarray analysis

Total RNA was extracted from the three pairs of aortic tissue samples from the patients with AS and controls. Total RNA was extracted and RNA quality was determined. The Quick Amp Labeling kit, One-Color (cat. no. 5190-2305; Agilent Technologies, Inc., Santa Clara, CA, USA) was used to carry out the labeling reaction, following which the labeled/amplified RNA was purified and the labeled cRNA quality was determined. Hybridization was performed using an Agilent Gene Expression Hybridization kit (cat. no. 5188-5242; Agilent Technologies, Inc.) according to the manufacturer\'s protocol and the microarray was washed. An Agilent microarray scanner (model G2565AA; Agilent Technologies, Inc.) was used and Agilent Feature Extraction software v.11.0.1.1 (Agilent Technologies, Inc.) was used to extract data.

The microarray was performed by KangChen Biotech (Zhejiang Kangchen Biotech Co., Ltd., Wuhan, China). By comparing the normalized expression levels in the AS and non-AS serum samples, differentially expressed lncRNAs with statistical significance (A/N or N/A fold change \>1.5, P\<0.05) were identified with a paired t test; A refers to AS and N refers to Normal).

### Mouse model of carotid artery ligation

The carotid artery ligation (CAL) was performed according to the protocol developed by Allagnat *et al* ([@b14-mmr-19-06-4663]), on 8-week-old male C57BL/6J mice, as previously described. Mice were fed standard laboratory chow and water *ad libitum*, and were housed in single cages under specific pathogen-free conditions (temperature and humidity were controlled at 22±2°C and 55±5%) in a room with a 12-h light/dark cycle. Male mice (weight, 20--25 g; age, 8 weeks) were used in the present study. Briefly, the mice were anesthetized with 4% chloral hydrate. The left common carotid artery was dissected through a small cervicotomy and ligated with prolene 7.0 just below the carotid bifurcation. The mice were sacrificed by cervical dislocation, and perfused with PBS followed by buffered paraformaldehyde 4% through the left ventricle prior to CAL for reference or on days 3, 14 or 28 days following CAL. All animal experimentation conformed to the Guidelines of the local Animal Care and Use Committee at Tangshan Workers Hospital.

### Cell culture

Mouse vascular smooth muscle cells (VSMCs) were purchased from the Institute of Biochemistry Cell Biology (Shanghai, China). The cells were cultured at 37°C in a humidified incubator with 5% CO~2~ and 95% air, and maintained in DMEM supplemented with 10% FBS and 1% penicillin/streptomycin (100 U/ml/100 mg/ml).

### Cell transfection

The VSMCs were seeded into the 6-well plates at a density of 5,000 cells/well, cultured for 24 h and then transfected when the cell density reached 70%. The siRNA sequences of lncRNA 430945 and ROR2 were as follows: si-lncRNA 430945: 5′-ACUCCUUCGUAUCUCGCCTT-3′, si-ROR2: 5′-AGUCUCUCAUAUCUUCGGT-3′ and a negative control (a scrambled matched %GC oligonucleotide). Following mixing of Lipofectamine^®^ 2000 with the pcDNA-lncRNA430945, pc-DNA, si-lncRNA430945, si-ROR2 or the negative transfection group (si-NC), and the mixture was added to the cells and incubated for 6 h. Complete medium was then used for culture for 24 h, following which the cells were collected for subsequent experiments.

### Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) analysis

Total RNA from the cells and clinical samples were obtained using the RNAiso Plus (Takara Bio, Inc., Otsu, Japan) and TRIzol LS reagent (Invitrogen; Thermo Fisher Scientific, Inc.) separately. A total of 0.5 µg RNA from each sample was reverse transcribed into cDNA using the PrimeScript™ RT reagent kit (Takara Bio, Inc., Otsu, Japan) according to the manufacturer\'s protocol. The mRNA expression levels were quantified using the standard qPCR protocol with SYBR Premix Ex Taq (Takara Bio, Inc.), which consisted of 40 cycles (95°C for 10 sec, 60°C for 10 sec and 72°C for 10 sec) following an initial denaturation step (95°C for 2 min). Relative expression levels of transcripts were normalized to GAPDH and calculated using the 2^−∆∆Cq^ formula as previously described ([@b15-mmr-19-06-4663],[@b16-mmr-19-06-4663]). The primer sequences used are listed in [Table I](#tI-mmr-19-06-4663){ref-type="table"}.

### Western blot assay

The VSMCs were grown in a 6-well plate. Total proteins were extracted by RIPA lysis buffer containing PMSF (Beyotime Institute of Biotechnology, Shanghai, China) at 4°C for 30 min. The supernatant protein levels were determined by standard BCA assay. An equal quantity of protein (50 µg) was loaded onto a 10% gel for sodium dodecyl sulfate polyacrylamide gel electrophoresis and then transferred onto a PVDF membrane (EMD Millipore, Billerica, MA, USA) following electrophoresis. Following the blocking of non-specific binding sites for 1 h at room temperature with 5% non-fat milk in TBST (Boster Biological Technology, Pleasanton, CA, USA), the membranes were individually incubated overnight with primary antibody anti-ROR2 (1:1,000, cat. no. 10616-1-AP; ProteinTech Group, Inc.), anti-RhoA (1:1,000, 10749-1-AP; ProteinTech Group, Inc.), anti-PCNA (1:1,000, cat. no. 10205-2-AP; ProteinTech Group, Inc.) and anti-MMP9 (1:1,000, 10375-2-AP; ProteinTech Group, Inc.) at 4°C. Membranes were washed in PBS with 0.1% Tween-20 and incubated with horseradish peroxidase-conjugated sheep anti-mouse IgG and sheep anti-rabbit IgG secondary antibodies (1:3,000; cat. nos. ZDR-5307 and ZDR-5306; OriGene Technologies, Inc. Beijing, China) at room temperature for 2 h, according to the manufacturer\'s instructions. The protein bands were revealed using the electrochemiluminescence method and images were captured using a BioSpectrum Gel Imaging system (Bio-Rad Laboratories, Inc., Hercules, CA, USA).

### Cell Counting Kit-8 (CCK8) assay ([@b4-mmr-19-06-4663])

Following appropriate treatment, the viability of the VSMCs cultured in 96-well plates was measured using the CCK8 assay kit (Dojindo Molecular Technologies, Inc., Kumamoto, Japan), as previously described. The absorbance at 450 nm was measured. Three controls were set in each group and the whole experiment was repeated three times.

### Wound-healing assay

The VSMCs were grown in medium to a confluence of 80--100% prior to the cell monolayer being scratched using a sterile micropipette tip. Following washes with PBS, fresh DMEM was added. Images of the wounded area were captured immediately following the scratch and 24 h later to monitor VSMC migration into the wounded region. The migratory abilities were quantified by measuring the total number of cells in the scratched regions.

### Transwell assays

A Transwell invasion assay was performed as described previously ([@b15-mmr-19-06-4663]). In brief, the VSMCs were loaded onto the upper well of the Transwell chamber with an 8-µm φ pore membrane (Costar; Corning, Inc., Corning, NY, USA), precoated with Matrigel on an upper side of the chamber. The lower well was filled with 500 µl of DMEM containing 10% FBS. Following incubation for 24 h, the cells invaded to lower surface of the membrane were counted using a Leica Wild M690 operating microscope with a ×40 objective (Leica Microsystems GmbH, Wetzlar, Germany).

### Determination of the protein levels of active Rho

The RhoA activity assays were performed according to the manufacturer\'s protocol (Upstate Cell Signaling Solutions, Lake Placid, NY). Active Rho (Rho-GTP) was isolated with a GST fusion protein containing the RhoA binding domain of rhotekin (GST-rhotekin RBD). The cells were washed with ice-cold PBS and lysed on ice in cell lysis buffer. Following determining the protein concentrations using the method of Bradford, 250 µg total protein per sample were incubated with GST-rhotekin RBD immobilized on glutathione-Sepharose 4B beads (GE Healthcare Life Sciences) at 4°C for 60 min. The beads were pelleted and washed three times with lysis buffer. Bound GTP-RhoA was eluted from the beads with SDS gel sample buffer, boiled for 5 min and separated by 12% SDS-PAGE. The active Rho proteins were detected by immunoblotting using anti-RhoA (ProteinTech Group, Inc.) antibody. Signals were quantified using ImageJ software 2× (National Institutes of Health, Bethesda, MD, USA).

### Statistical analysis

All results are presented as the mean ± standard deviation. A one-way analysis of variance followed by Tukey\'s or Dunnett\'s post hoc test was used to analyze the differences between multiple groups using SPSS 13.0 (SPSS, Inc., Chicago, IL, USA) and GraphPad Prism 5.0 (GraphPad Software, Inc., La Jolla, CA, USA). Two-sided P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Expression of lncRNA 430945 and ROR2 is upregulated in human AS tissues

Hematoxylin and eosin staining revealed a higher number of VSMCs in human AS tissues than in control tissues ([Fig. 1A](#f1-mmr-19-06-4663){ref-type="fig"}). To determine differentially expressed lncRNAs and their associated mRNAs in human AS tissues, microarray analysis was performed using atherosclerotic and normal aorta tissue samples from patients with AS and healthy donors. Differentially expressed lncRNAs were selected only when they were altered by a fold-change cut-off value of 2.0. As shown in [Fig. 1B](#f1-mmr-19-06-4663){ref-type="fig"}, the 20 lncRNA transcripts with the highest significant differential expression patterns are listed, with lncRNA 430945 being the most markedly upregulated. [Fig. 1C](#f1-mmr-19-06-4663){ref-type="fig"} shows 15 differentially expressed mRNAs identified through lncRNA microarray analysis with a fold-change cut-off of 2.0 (P\<0.05), with ROR2 mRNA being the most markedly upregulated. qPCR validation indicated good reliability and reproducibility of the lncRNA 430945 change determined by RNA-seq ([Fig. 1D](#f1-mmr-19-06-4663){ref-type="fig"}). The qPCR and western blotting results revealed higher expression of ROR2 at the transcriptional ([Fig. 1E](#f1-mmr-19-06-4663){ref-type="fig"}) and translational levels ([Fig. 1F](#f1-mmr-19-06-4663){ref-type="fig"}) in human AS tissues than in control tissues. These results suggest that lncRNA 430945 and ROR2 are involved in the phenotypic transition of VSMCs and AS tissues.

### lncRNA 430945 promotes VSMC proliferation and migration

The overexpression of lncRNA 430945 in VSMCs was induced to examine its effect on cell function ([Fig. 2A](#f2-mmr-19-06-4663){ref-type="fig"}). CCK8, wound-healing and Transwell assays were used to examine the effect of lncRNA 430945 on the proliferation and migration of VSMCs. Consequently, it was found that the VSMCs exhibited increased proliferation (Fig. C) and migration ([Fig. 2B-D](#f2-mmr-19-06-4663){ref-type="fig"}). Furthermore, western blotting revealed that the overexpression of lncRNA 430945 significantly increased the expression of ROR2 ([Fig. 2E](#f2-mmr-19-06-4663){ref-type="fig"}). These results suggest that lncRNA 430945 promotes VSMC proliferation and migration, thereby accelerating the development of AS.

### ROR2 is involved in lncRNA 430945-mediated AngII-induced VSMC proliferation and migration

The AngII-induced dysfunction of VSMCs is crucial in the development of AS. As lncRNA 430945 exhibited high expression in AS tissues, the present study examined whether lncRNA 430945 can influence the AngII-induced proliferation and migration of VSMCs. The expression of lncRNA 430945 was determined in VSMCs following AngII treatment and transfection with lncRNA 430945 siRNA for 24--48 h, following which PCR was performed. As shown in [Fig. 3A and B](#f3-mmr-19-06-4663){ref-type="fig"}, AngII treatment significantly increased the expression of lncRNA 430945 in VSMCs; the expression of lncRNA 430945 in VSMCs transfected with si-lncRNA 430945 was markedly lower than that in VSMCs transfected with si-NC. Furthermore, the downregulation of lncRNA 430945 in VSMCs transfected with si-lncRNA 430945 led to significantly higher suppression of AngII-induced proliferation and migration than in the VSMCs transfected with si-NC ([Fig. 3C-E](#f3-mmr-19-06-4663){ref-type="fig"}). The, siRNA-mediated knockdown of lncRNA 430945 reduced the AngII-induced and basal expression of ROR2 ([Fig. 3F](#f3-mmr-19-06-4663){ref-type="fig"}). Together, these results suggest that lncRNA 430945 affects the expression of ROR2 and thereby mediates AngII-induced VSMC proliferation and migration.

### lncRNA 430945 promotes the proliferation and migration of VSMCs in a ROR2-dependent manner

As the overexpression of lncRNA 430945 was linked to the upregulation of ROR2 in VSMCs and in AS tissues, a decrease in the expression of ROR2 in VSMCs was induced using si-ROR2 to further clarify the association between lncRNA 430945 and ROR2. Western blotting showed that the expression of ROR2 in the si-ROR2-treated VSMCs was significantly lower than that in the si-NC-treated VSMCs ([Fig. 4A](#f4-mmr-19-06-4663){ref-type="fig"}). The CCK8 assay showed that VSMC proliferation was markedly lower following transfection with si-ROR2 than that in the si-NC-transfected VSMCs and control cells ([Fig. 4B](#f4-mmr-19-06-4663){ref-type="fig"}). As the upregulation of lncRNA 430945 increased cell proliferation and migration, the present study ascertained whether VSMC proliferation and migration were also modified in response to increased lncRNA 430945, and whether si-ROR2 influenced the cell proliferation and migration induced by lncRNA 430945. As shown in [Fig. 4C-E](#f4-mmr-19-06-4663){ref-type="fig"}, si-ROR2 significantly reduced VSMC proliferation and migration, irrespective of whether lncRNA 430945 was upregulated. These data revealed that lncRNA 430945 promotes VSMC proliferation and migration by upregulating the expression of ROR2.

### LncRNA 430945 activates the RhoA signaling pathway in VSMCs

The expression of ROR2 affects the RhoA signaling pathway, which is an essential intracellular signaling pathway, and is involved in cellular proliferation and migration during the development of AS ([@b17-mmr-19-06-4663],[@b18-mmr-19-06-4663]). Therefore, the present study aimed to discern whether lncRNA 430945 regulates VSMC proliferation and migration via the ROR2/RhoA signaling pathway. The results revealed that the levels of GTP-RhoA, PCNA and MMP9 in VSMCs transfected with si-lncRNA 430945 were markedly lower than those in VSMCs transfected with si-NC ([Fig. 5A](#f5-mmr-19-06-4663){ref-type="fig"}). By contrast, the levels of GTP-RhoA, PCNA and MMP9 in VSMCs transfected with pcDNA-lncRNA430945 were markedly higher than those in VSMCs transfected with pcDNA-NC ([Fig. 5B](#f5-mmr-19-06-4663){ref-type="fig"}). The total RhoA levels in all the cells remained unchanged. This indicated that lncRNA 430945 is positively correlated with the ROR2/RhoA signaling pathway in VSMCs.

The present study also attempted to elucidate the mechanisms underlying lncRNA 430945-mediated AngII-induced VSMC proliferation and migration. Treating VSMCs with AngII significantly increased the expression of lncRNA 430945 and ROR2, and activated the GTP-RhoA signaling pathway, whereas repressing the expression of lncRNA 430945 and ROR2 inhibited the VSMC proliferation and migration induced by AngII. In addition, a mouse model of carotid artery ligation-induced intimal thickening and proliferation was used to evaluate the protective effect of si-lncRNA 430945 on vascular remodeling. As shown in [Fig. 5C and D](#f5-mmr-19-06-4663){ref-type="fig"}, si-lncRNA 430945 treatment following surgery effectively inhibited vascular intimal hyperplasia compared with that in the si-NC treatment group.

Discussion
==========

Activated VSMCs may contribute to the progression and eventual rupture of atherosclerotic plaques ([@b19-mmr-19-06-4663]). Therefore the main purpose of the present study was to identify potential molecular targets to inhibit VSMC proliferation and migration. It was found that AngII increased lncRNA 430945-mediated VSMC proliferation and migration by upregulating the expression of ROR2 and activating the RhoA signaling pathway. By contrast, inhibiting lncRNA 430945 or ROR2 suppressed the AngII-induced VSMC proliferation and migration by inactivating the RhoA signaling pathway.

It has been shown that lncRNAs are involved in the development of AS, and certain lncRNAs may be promising as potential drug targets for treating AS ([@b20-mmr-19-06-4663],[@b21-mmr-19-06-4663]). LncRNAs HOXC-AS1 and HOXC6 are downregulated in carotid AS ([@b22-mmr-19-06-4663]). In addition, lnc00113 is upregulated in AS, which indicates it may promote cell survival, proliferation and migration by activating the PI3K/Akt/mTOR signaling pathway ([@b21-mmr-19-06-4663]). To clarify the role of lncRNAs in AS in the present study, microarray analysis and lncRNA-mRNA co-expression profiling were performed by using tissue samples from patients with AS and healthy volunteers. It was found that lncRNA 430945 and ROR2 were considerably upregulated, which were selected for ascertaining their role in AS. It has also been reported that the expression of lncRNA-RNCR3 is high in the mouse and human aortic AS. The proliferation and migration of VSMCs is suppressed when the expression of lncRNA-RNCR3 decreases, suggesting that lncRNARNCR3 is a putative target in treating AS ([@b23-mmr-19-06-4663]). Another regulatory factor, lincRNA-p21, regulates neointima formation, VSMC proliferation, apoptosis and atherosclerotic plaque development by enhancing the activity of p53 ([@b24-mmr-19-06-4663]), suggesting that lncRNAs may serve as therapeutic targets for treating AS and other vascular diseases. To the best of our knowledge, the present study is the first to report that a link exists between lncRNA 430945 and AS. The downregulation of lncRNA 430945 significantly suppressed VSMC proliferation and migration via ROR2, indicating that lncRNA 430945 and ROR2 are important in the development of AS.

Rho small GTPases regulate a variety of cellular functions, including proliferation, migration and invasion. RhoA is required for atherosclerotic AngII-induced VSMC proliferation. The present study also confirmed that lncRNA 430945 regulated the RhoA signaling pathway. In addition, lncRNA 430945 modulated the expression of ROR2, which in turn regulated the expression of PCNA and MMP9 in VSMCs. Therefore, lncRNA 430945/ROR2 promoted VSMC proliferation and migration in a hypertensive state by activating the RhoA pathway. Resveratrol has been shown to prevent AngII-induced hypertension and SMC proliferation via AMPK activation and inhibition of the RhoA/Rho-associated protein kinase signaling pathway *in vivo* and *in vitro*, highlighting a novel therapeutic target with anti-atherosclerotic properties ([@b25-mmr-19-06-4663]). It has also been found that naringin treatment inhibits the TNFα-induced RhoA pathway in VSMCs, which provides a theoretical basis for the prevention of AS ([@b26-mmr-19-06-4663]). In view of this, it is evident that lncRNA 430945 can activate the RhoA pathway, suggesting that the inactivation of lncRNA 430945 or RhoA signaling may suppress the development and progression of AS.

In conclusion, the findings reported here provide evidence that lncRNA 430945 promotes VSMC proliferation and migration by upregulating the expression of ROR2 and activating the RhoA signaling pathway. It was shown that the upregulation of lncRNA 430945 promoted ROR2 and RhoA signaling pathways, contributing to the AngII-induced proliferation and migration of VSMCs and AS. Further investigations are necessary to validate the potential of these results, so that an effective therapeutic strategy can be designed to potentially treat AS in humans.
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![Expression of lncRNA 430945 and ROR2 are high in human AS tissues. (A) Hematoxylin and eosin-stained representative sections of aortas from human AS tissues and Con tissues. Scale bar=50 µm. Subset of the differentially expressed (B) lncRNAs and (C) mRNAs detected in the AS tissues (n=3) and Con tissues (n=3) using microarray analysis. (D) Six lncRNAs with differential expression in AS tissues and Con tissues were validated by qPCR. (E) Expression levels of ROR2 in AS tissues and Con tissues were analyzed using qPCR. \*P\<0.05, vs. Con (n=3). (F) Levels of ROR2 in AS tissues and Con tissues were analyzed using western blotting. The band intensities relative to β-actin are presented as the mean ± standard deviation; n=3; \*P\<0.05, vs. Con. ROR2, receptor tyrosine kinase-like orphan receptor 2; lncRNAs, long non-coding RNAs; qPCR, quantitative-polymerase chain reaction; AS, atherosclerosis; Con, control (normal aortic tissues).](MMR-19-06-4663-g00){#f1-mmr-19-06-4663}

![lncRNA 430945 promotes VSMC proliferation and migration. (A) VSMCs were transfected with pcDNA or pcDNA-lncRNA430945 for 24 h and the expression of lncRNA 430945 was analyzed by quantitative polymerase chain reaction analysis. \*P\<0.05, vs. control (n=3). (B) VSMC monolayers were pre-treated with pcDNA or pcDNA-lncRNA430945 for 24 h prior to being wounded, and cells migrating to the scratch gap were quantified (magnification, ×100). The data are presented as the mean ± standard deviation from three independent experiments. \*P\<0.05, vs. pcDNA. (C) Cell growth was assessed using a cell viability Cell Counting Kit-8 assay following transfection with pcDNA or pcDNA-lncRNA430945 for 0, 12, 24, 36 and 48 h. \*P\<0.05 and \*\*P\<0.01 vs. pcDNA at different times (n=3). (D) Representative photomicrographs of a Transwell assay showing the quantification of VSMC invasion (magnification, ×400). The number of invaded cells was measured in three separate experiments and data represent the mean ± standard deviation (n=3). \*P\<0.05, vs. pcDNA group. (E) VSMCs were transfected with pcDNA or pcDNA-lncRNA430945 for 24 h and total cell lysates were analyzed by western blotting with anti-ROR2 antibody. \*P\<0.05, vs. pcDNA (n=3). VSMCs, vascular smooth muscle cells; ROR2, receptor tyrosine kinase-like orphan receptor 2; lncRNAs, long non-coding RNAs.](MMR-19-06-4663-g01){#f2-mmr-19-06-4663}

![lncRNA 430945 mediates AngII-induced VSMC proliferation, migration and invasion. (A) VSMCs were stimulated with AngII for 24 h and the expression of lncRNA 430945 was analyzed using qPCR. \*P\<0.05, vs. control (n=3). (B) VSMCs were transfected with non-specific siRNA (si-NC) or lncRNA 430945-specifc siRNA (si-lncRNA 430945) for 24 h and the expression of lncRNA 430945 was analyzed using qPCR. \*P\<0.05, vs. control (n=3). (C) VSMCs were pre-treated with si-NC or si-lncRNA 430945 for 24 h prior to being stimulated with AngII for an additional 0, 12, 24, 36 or 48 h. Cell growth was assessed using the cell viability Cell Counting Kit-8 assay. \*P\<0.05 and \*\*\*P\<0.001, vs. si-NC at different time (n=3). (D) VSMC monolayers were pre-treated with si-NC or si-lncRNA 430945 for 24 h prior to being wounded and then stimulated with or without AngII for 0 and 24 h, and cell migration was assessed under phase-contrast light microscopy (magnification, ×100). (E) Representative photomicrographs of a Transwell assay show the quantification of VSMC invasion (magnification, ×400). The number of invaded cells was measured in three separate experiments and data represent the mean ± standard deviation (n=3). \*P\<0.05 and \*\*P\<0.01, vs. si-NC. (F) VSMCs were transfected with si-NC or si-lncRNA 430945 for 24 h and total cell lysates were analyzed by western blotting with anti-ROR2 antibody. \*P\<0.05, vs. si-NC (n=3). VSMCs, vascular smooth muscle cells; ROR2, receptor tyrosine kinase-like orphan receptor 2; lncRNAs, long non-coding RNAs; si-, small interfering RNA; NC, negative control; AngII, angiotensin II; qPCR, quantitative polymerase chain reaction.](MMR-19-06-4663-g02){#f3-mmr-19-06-4663}

![lncRNA 430945 promotes ROR2-dependent VSMC proliferation and migration. (A) ROR2 knockdown in VSMCs transfected with ROR2-specifc siRNA (si-ROR2) for 24 h was confirmed by western blotting with anti-ROR2 antibody. \*P\<0.05, vs. si-NC (n=3). (B) Cell growth was assessed by a cell viability CCK8 assay following transfection with si-NC or si-ROR2 for 0, 12, 24, 36 and 48 h. \*\*P\<0.01, vs. si-NC at different time (n=3). (C) VSMCs were pre-treated with si-lncRNA 430945 for 24 h prior to being transfected with pcDNA or pcDNA-lncRNA430945 for an additional 0, 12, 24, 36 or 48 h. Cell growth was assessed by a cell viability CCK8 assay. \*\*P\<0.01, vs. pcDNA at different time (n=3). (D) VSMC monolayers were pre-treated with cDNA or pcDNA-lncRNA430945 for 24 h prior to being wounded and then transfected with or without si-ROR2 for 0 and 24 h, and cell migration was assessed under phase-contrast light microscopy (magnification, ×100). Quantification of cells migrating into the scratch gap. \*\*P\<0.01, vs. pcDNA (n=3). (E) Transwell assay for the quantification of VSMC invasion (magnification, ×400). \*\*P\<0.01 vs. pcDNA (n=3). VSMCs, vascular smooth muscle cells; ROR2, receptor tyrosine kinase-like orphan receptor 2; lncRNAs, long non-coding RNAs; si-, small interfering RNA; NC, negative control; CCK8, Cell Counting Kit-8.](MMR-19-06-4663-g03){#f4-mmr-19-06-4663}

![lncRNA 430945 activates the RhoA signaling pathway and promotes the expression of PCNA and MMP9 in VSMCs. VSMCs were transfected with (A) si-NC and si-lncRNA 430945 or with (B) pcDNA and pcDNA-lncRNA430945. GTP-bound RhoA levels were determined by GST pull-down and immunoblotting with anti-RhoA antibody. The expression levels of PCNA and MMP9 was analyzed by western blotting with anti-PCNA and anti-MMP9 antibodies. Band intensities were measured and normalized to β-actin and are shown below. \*P\<0.05, vs. si-NC or pcDNA (n=3). (C) Representative images of HE-stained carotids of C57BL/6 mice treated with si-NC or si-lncRNA 430945 for 14 days. (D) Morphometric measurements of I/M ratio in carotids (magnification, ×200). Data are presented as the mean ± standard deviation (n=5 per group). \*P\<0.001, vs. Model + si-NC group. lncRNAs, long non-coding RNAs; si-, small interfering RNA; NC, negative control; PCNA, proliferating cell nuclear antigen; MMP9, matrix metallopeptidase 9; RhoA, Ras homolog gene family member A; HE, hematoxylin and eosin; I/M, intima/media.](MMR-19-06-4663-g04){#f5-mmr-19-06-4663}

###### 

Primers used for quantitative polymerase chain reaction.

  Name            Primer (5′-3′)
  --------------- -------------------------------------
  lncRNA 430945   Forward: GAGGCTGAGACGGGCGACCA
                  Reverse: CGTGGGCCTCTTAGAAGCAGC
  ROR2            Forward: ATTGGGAACCGAACTATTTATG
                  Reverse: TCTGACAGGTGCGTGGAG
  GAPDH           Forward: CTCAACTACATGGTCTACATGTTCCA
                  Reverse: CTTCCCATTCTCAGCCTTGACT

lncRNA, long non-coding RNA; ROR2, receptor tyrosine kinase-like orphan receptor 2.
